{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:56:37Z","timestamp":1786661797076,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Enzalutamide, a second-generation androgen receptor inhibitor, is indicated for the treatment of metastatic disease, as well as in the treatment of non-metastatic castration resistant prostate cancer (PCa). This systematic review aims to determine outcomes and toxicity in patients with non-metastatic castration sensitive prostate cancer (nmCSPC) treated with enzalutamide in the primary or salvage settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We performed a systematic review focusing on the role of Enzalutamide in the treatment of nmCSPC, using the PubMed\/Medline database. Articles focusing on androgen receptor inhibitors in nmCSPC were included, while articles discussing exclusively metastatic or castration-resistant PCa were excluded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The initial search retrieved 401 articles, of which 15 underwent a thorough assessment for relevance. Ultimately, 12 studies with pertinent outcomes were meticulously examined. Among these, seven studies were dedicated to the investigation of enzalutamide in the primary setting, while the remaining five publications specifically addressed its use in salvage settings. Regardless of the treatment setting, our data revealed two distinct therapeutic strategies. The first advocates for the substitution of enzalutamide for androgen deprivation therapy (ADT), based on the premise of achieving equivalent, if not superior, oncological outcomes while minimizing treatment-related toxicity. The second, adopting a more conventional approach, entails augmenting the effectiveness of ADT by incorporating enzalutamide.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Enzalutamide has considerable potential as a therapeutic strategy for nmCSPC, either used alone or in combination with ADT in the primary or in the salvage settings. The use of enzalutamide instead of ADT is an appealing strategy. However, more trials will be required to further understand the efficacy and side-effect profile of enzalutamide monotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41391-024-00829-9","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T18:02:16Z","timestamp":1712599336000},"page":"422-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6477-6655","authenticated-orcid":false,"given":"Mohamed","family":"Shelan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9rane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Appiagyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0693-2716","authenticated-orcid":false,"given":"Lucas","family":"Mose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D.","family":"Fankhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-3834","authenticated-orcid":false,"given":"Daniel M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"829_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","volume":"31","author":"G Carioli","year":"2020","unstructured":"Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E, et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol. 2020;31:650\u20138.","journal-title":"Ann Oncol"},{"key":"829_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390166","volume":"43","author":"AA Hamid","year":"2023","unstructured":"Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"829_CR3","first-page":"243","volume":"15","author":"S Ferretti","year":"2023","unstructured":"Ferretti S, Mercinelli C, Marandino L, Litterio G, Marchioni M, Schips L. Metastatic castration-resistant prostate cancer: insights on current therapy and promising experimental drugs. Res Rep Urol. 2023;15:243\u201359.","journal-title":"Res Rep Urol"},{"key":"829_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102525","volume":"115","author":"A Berruti","year":"2023","unstructured":"Berruti A, Bracarda S, Caffo O, Cortesi E, D\u2019Angelillo R, Del Re M, et al. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives. Cancer Treat Rev. 2023;115:102525.","journal-title":"Cancer Treat Rev"},{"key":"829_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"829_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"829_CR7","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197\u2013206.","journal-title":"N Engl J Med"},{"key":"829_CR8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465\u201374.","journal-title":"N Engl J Med"},{"key":"829_CR9","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"829_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:323\u201334.","journal-title":"Lancet Oncol"},{"key":"829_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.","journal-title":"Bmj"},{"key":"829_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453\u201365.","journal-title":"N Engl J Med"},{"key":"829_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447\u201360.","journal-title":"Lancet"},{"key":"829_CR14","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.ijrobp.2021.02.027","volume":"110","author":"I Kaplan","year":"2021","unstructured":"Kaplan I, Bubley GJ, Bhatt RS, Taplin ME, Dowling S, Mahoney K, et al. Enzalutamide with radiation therapy for intermediate-risk prostate cancer: a phase 2 study. Int J Radiat Oncol Biol Phys. 2021;110:1416\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"829_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891886","volume":"12","author":"PC Lara","year":"2022","unstructured":"Lara PC, Rodr\u00edguez-Melc\u00f3n JI, Palacios-Eito A, Lozano A, Herv\u00e1s-Mor\u00f3n A, Villafranca E, et al. Phase II study of ENZAlutamide combined with hypofractionated radiation therapy (ENZART) for localized intermediate risk prostate cancer. Front Oncol. 2022;12:891886.","journal-title":"Front Oncol"},{"key":"829_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1200\/JCO.18.01777","volume":"37","author":"RR McKay","year":"2019","unstructured":"McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncol. 2019;37:923\u201331.","journal-title":"J Clin Oncol"},{"key":"829_CR17","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","volume":"23","author":"B Montgomery","year":"2017","unstructured":"Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, et al. Neoadjuvant enzalutamide prior to prostatectomy. Clin Cancer Res. 2017;23:2169\u201376.","journal-title":"Clin Cancer Res"},{"key":"829_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100941","volume":"7","author":"K Shee","year":"2022","unstructured":"Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, et al. Addition of enzalutamide to leuprolide and definitive radiation therapy is tolerable and effective in high-risk localized or regional nonmetastatic prostate cancer: results from a phase 2 trial. Adv Radiat Oncol. 2022;7:100941.","journal-title":"Adv Radiat Oncol"},{"key":"829_CR19","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","volume":"8","author":"ND Shore","year":"2022","unstructured":"Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, et al. Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial. JAMA Oncol. 2022;8:1128\u201336.","journal-title":"JAMA Oncol"},{"key":"829_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.euo.2020.01.005","volume":"4","author":"RL Bitting","year":"2021","unstructured":"Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, et al. Phase II trial of enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: the STREAM trial. Eur Urol Oncol. 2021;4:948\u201354.","journal-title":"Eur Urol Oncol"},{"key":"829_CR21","doi-asserted-by":"crossref","unstructured":"Madan RA, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner II, et al. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. J Immunother Cancer. 2021;9:e001556.","DOI":"10.1136\/jitc-2020-001556"},{"key":"829_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.juro.2017.08.103","volume":"199","author":"B Tombal","year":"2018","unstructured":"Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Long-term antitumor activity and safety of enzalutamide monotherapy in hormone Na\u00efve prostate cancer: 3-year open label followup results. J Urol. 2018;199:459\u201364.","journal-title":"J Urol"},{"key":"829_CR23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1200\/JCO.22.01662","volume":"41","author":"PT Tran","year":"2023","unstructured":"Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, et al. Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial. J Clin Oncol. 2023;41:1307\u201317.","journal-title":"J Clin Oncol"},{"key":"829_CR24","unstructured":"Mottet NCP, van den Bergh RCN, et al. EAU guidelines 2023 [Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment."},{"key":"829_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.euros.2022.09.022","volume":"46","author":"J G\u00f3mez Rivas","year":"2022","unstructured":"G\u00f3mez Rivas J, Gandaglia G, Montorsi F. Re: Neal D. Shore, Joseph Renzulli, N E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36: Let\u2019s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice. Eur Urol Open Sci. 2022;46:135\u20136.","journal-title":"Eur Urol Open Sci"},{"key":"829_CR26","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1200\/JCO.2008.18.2501","volume":"27","author":"AJ Stephenson","year":"2009","unstructured":"Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300\u20135.","journal-title":"J Clin Oncol"},{"key":"829_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/aja.aja_96_20","volume":"23","author":"W Liu","year":"2021","unstructured":"Liu W, Yao Y, Liu X, Liu Y, Zhang GM. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2021;23:429\u201336.","journal-title":"Asian J Androl"},{"key":"829_CR28","first-page":"Cd006019","volume":"2006","author":"S Kumar","year":"2006","unstructured":"Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;2006:Cd006019.","journal-title":"Cochrane Database Syst Rev"},{"key":"829_CR29","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1200\/JCO.22.02390","volume":"41","author":"DJ Krauss","year":"2023","unstructured":"Krauss DJ, Karrison T, Martinez AA, Morton G, Yan D, Bruner DW, et al. Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial. J Clin Oncol. 2023;41:3203\u201316.","journal-title":"J Clin Oncol"},{"key":"829_CR30","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","volume":"34","author":"M Bolla","year":"2016","unstructured":"Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34:1748\u201356.","journal-title":"J Clin Oncol"},{"key":"829_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1012348","volume":"365","author":"CU Jones","year":"2011","unstructured":"Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107\u201318.","journal-title":"N Engl J Med"},{"key":"829_CR32","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388\u201399.","journal-title":"Cancer"},{"key":"829_CR33","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.23.00617","volume":"41","author":"S Roy","year":"2023","unstructured":"Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, et al. Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate. J Clin Oncol. 2023;41:5005\u201314.","journal-title":"J Clin Oncol"},{"key":"829_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ijrobp.2021.12.160","volume":"113","author":"A Tree","year":"2022","unstructured":"Tree A, Griffin C, Syndikus I, Birtle A, Choudhury A, Graham J, et al. Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) analogs in combination with radiation therapy in the CHHiP trial. Int J Radiat Oncol Biol Phys. 2022;113:305\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"829_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109544","volume":"183","author":"N-S Schmidt-Hegemann","year":"2023","unstructured":"Schmidt-Hegemann N-S, Zamboglou C, Mason M, Mottet N, Hinnen K, De Meerleer G, et al. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiother Oncol. 2023;183:109544.","journal-title":"Radiother Oncol"},{"key":"829_CR36","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886\u2013901.","journal-title":"Lancet"},{"key":"829_CR37","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magne N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20:1740\u20139.","journal-title":"Lancet Oncol"},{"key":"829_CR38","doi-asserted-by":"publisher","first-page":"S1427","DOI":"10.1016\/j.annonc.2022.08.064","volume":"33","author":"CC Parker","year":"2022","unstructured":"Parker CC, Clarke N, Cook A, Catton C, Cross WR, Kynaston H, et al. LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031). Ann Oncol. 2022;33:S1427.","journal-title":"Ann Oncol"},{"key":"829_CR39","doi-asserted-by":"publisher","first-page":"S1428","DOI":"10.1016\/j.annonc.2022.08.067","volume":"33","author":"S Burdett","year":"2022","unstructured":"Burdett S, Fisher D, Parker CC, Sydes MR, Pommier P, Sargos P, et al. LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data. Ann Oncol. 2022;33:S1428\u2013S9.","journal-title":"Ann Oncol"},{"key":"829_CR40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","volume":"6","author":"RT Dess","year":"2020","unstructured":"Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, et al. Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol. 2020;6:735\u201343.","journal-title":"JAMA Oncol"},{"key":"829_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376:417\u201328.","journal-title":"N Engl J Med"},{"key":"829_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","volume":"68","author":"B Tombal","year":"2015","unstructured":"Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Long-term efficacy and safety of enzalutamide monotherapy in hormone-na\u00efve prostate cancer: 1- and 2-year open-label follow-up results. Eur Urol. 2015;68:787\u201394.","journal-title":"Eur Urol"},{"key":"829_CR43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","volume":"15","author":"B Tombal","year":"2014","unstructured":"Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014;15:592\u2013600.","journal-title":"Lancet Oncol"},{"key":"829_CR44","doi-asserted-by":"publisher","first-page":"e046588","DOI":"10.1136\/bmjopen-2020-046588","volume":"11","author":"SJ Freedland","year":"2021","unstructured":"Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, et al. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open. 2021;11:e046588.","journal-title":"BMJ Open"},{"key":"829_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.23736\/S0393-2249.18.03081-3","volume":"70","author":"A Eissa","year":"2018","unstructured":"Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, et al. The role of 68Ga-PSMA PET\/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018;70:462\u201378.","journal-title":"Minerva Urol Nefrol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00829-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00829-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00829-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T10:03:06Z","timestamp":1723456986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00829-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1038\/s41391-024-00829-9","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS received honoraria and travel costs (institutional) from Janssen and Debiopharm, along with research grants from Debiopharm. Additionally, MS served on advisory boards for Astellas. VA served as a speaker for Janssen and Accor Healthcare and provided consultancy for Astellas. TZ disclosed receiving honoraria and travel costs (institutional) from Janssen, Amgen, Ferring, Debiopharm, Bayer, Astellas, Telix, and MVison, research grants from Varian Medical Systems, and advisory board roles with Janssen, Accord, and Astellas. RC declared an advisory role (institutional) with Astellas, Bayer, Janssen, Sanofi, Debiopharm, BMS, MSD, Roche, Novartis, Pfizer, Merck,\u00a0and Ipsen, along with honoraria (institutional) from Astellas, Janssen, and Novartis. All other authors reported no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}